BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS

Maria Teresa Esposito

BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS

Maria Teresa Esposito (Inventor)

Research output: Patent

29 Downloads (Pure)

Abstract

In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML

Original language	English
Patent number	514/34
IPC	C12Q1/68; A61K31/4184; A61K31/502; A61K45/06
Priority date	17/09/14
Publication status	Published - 21 Jul 2016

Keywords

biomarkers
leukemia
PARP inhibitor
DNA damage

Access to Document

patent Esposito MT

Cite this

@misc{c923dbbec37b4da489d5d40e96925a84,

title = "BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS",

abstract = "In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML",

keywords = "biomarkers, leukemia, PARP inhibitor, DNA damage",

author = "Esposito, {Maria Teresa}",

year = "2016",

month = jul,

day = "21",

language = "English",

type = "Patent",

note = "514/34; C12Q1/68; A61K31/4184; A61K31/502; A61K45/06 ",

}

TY - PAT

T1 - BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS

AU - Esposito, Maria Teresa

PY - 2016/7/21

Y1 - 2016/7/21

N2 - In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML

AB - In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML

KW - biomarkers

KW - leukemia

KW - PARP inhibitor

KW - DNA damage

M3 - Patent

M1 - 514/34

ER -